DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc.verified

DMAC

Price:

$5.43

Market Cap:

$232.19M

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutic...[Read more]

Industry

Biotechnology

IPO Date

2012-08-03

Stock Exchange

NASDAQ

Ticker

DMAC

The PE Ratio as of December 2024 (TTM) for DiaMedica Therapeutics Inc. (DMAC) is -9.70

According to DiaMedica Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -9.70. This represents a change of 69.63% compared to the average of -5.72 of the last 4 quarters.

DiaMedica Therapeutics Inc. (DMAC) Historical PE Ratio (quarterly & annually)

How has DMAC PE Ratio performed in the past?

The mean historical PE Ratio of DiaMedica Therapeutics Inc. over the last ten years is -5.28. The current -9.70 PE Ratio has changed 18.29% with respect to the historical average. Over the past ten years (40 quarters), DMAC's PE Ratio was at its highest in in the December 2014 quarter at -1.06. The PE Ratio was at its lowest in in the September 2018 quarter at -32.21.

Quarterly (TTM)
Annual

Average

-5.28

Median

-4.77

Minimum

-12.94

Maximum

-0.64

DiaMedica Therapeutics Inc. (DMAC) PE Ratio by Quarter and Year

Discovering the peaks and valleys of DiaMedica Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 640.27%

Maximum Annual PE Ratio = -0.64

Minimum Annual Increase = -88.63%

Minimum Annual PE Ratio = -12.94

Quarterly (TTM)
Annual
YearPE RatioChange
2023-4.7756.21%
2022-3.05-46.41%
2021-5.70-55.93%
2020-12.94136.92%
2019-5.4638.93%
2018-3.93-42.21%
2017-6.8045.09%
2016-4.69-1.84%
2015-4.77640.27%
2014-0.64-88.63%

DiaMedica Therapeutics Inc. (DMAC) Average PE Ratio

How has DMAC PE Ratio performed in the past?

The current PE Ratio of DiaMedica Therapeutics Inc. (DMAC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-4.51

5-year avg

-6.38

10-year avg

-5.28

DiaMedica Therapeutics Inc. (DMAC) PE Ratio vs. Peers

How is DMAC’s PE Ratio compared to its peers?

DiaMedica Therapeutics Inc.’s PE Ratio is less than Milestone Pharmaceuticals Inc. (-2.85), less than Seres Therapeutics, Inc. (-5.88), less than Inhibikase Therapeutics, Inc. (-1.37), less than Oncolytics Biotech Inc. (-3.70), less than scPharmaceuticals Inc. (-1.98), less than aTyr Pharma, Inc. (-2.33), less than Lyra Therapeutics, Inc. (-0.12), greater than Centessa Pharmaceuticals plc (-12.04), less than Iovance Biotherapeutics, Inc. (-5.48), less than X4 Pharmaceuticals, Inc. (0), less than Galera Therapeutics, Inc. (-6.82), less than Terns Pharmaceuticals, Inc. (-0.09), less than Day One Biopharmaceuticals, Inc. (-5.13), greater than HOOKIPA Pharma Inc. (-14.42), less than null (-0.54),

Build a custom stock screener for DiaMedica Therapeutics Inc. (DMAC) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like DiaMedica Therapeutics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

DiaMedica Therapeutics Inc. (DMAC) and other stocks custom spreadsheet templates

The easiest way to analyze a company like DiaMedica Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is DiaMedica Therapeutics Inc.'s PE Ratio?

How is the PE Ratio calculated for DiaMedica Therapeutics Inc. (DMAC)?

What is the highest PE Ratio for DiaMedica Therapeutics Inc. (DMAC)?

What is the 3-year average PE Ratio for DiaMedica Therapeutics Inc. (DMAC)?

What is the 5-year average PE Ratio for DiaMedica Therapeutics Inc. (DMAC)?

How does the current PE Ratio for DiaMedica Therapeutics Inc. (DMAC) compare to its historical average?